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Growth Factors, Cytokines, Cell Cycle Molecules
Macrophage-Specific Expression of Human
Lysosomal Acid Lipase Corrects Inflammation and
Pathogenic Phenotypes in lal/ Mice
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From The Center for Immunobiology,* Department of Pathology
and Laboratory Medicine, Indiana University School of Medicine,
Indianapolis, Indiana; the Division of Human Genetics,†
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and the Institute for Molecular Bioscience,‡ University of
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Lysosomal acid lipase (LAL) hydrolyzes cholesteryl
esters and triglycerides to generate free fatty acids
and cholesterol in the cell. The downstream metabo-
lites of these compounds serve as hormonal ligands
for nuclear receptors and transcription factors. Ge-
netic ablation of the lal gene in the mouse caused
malformation of macrophages and inflammation-trig-
gered multiple pathogenic phenotypes in multiple
organs. To assess the relationship between macro-
phages and lal/ pathogenic phenotypes, a macro-
phage-specific doxycycline-inducible transgenic sys-
tem was generated to induce human LAL (hLAL)
expression in the lal/ genetic background under
control of the 7.2-kb c-fms promoter/intron2 regula-
tory sequence. Doxycycline-induced hLAL expression
in macrophages significantly ameliorated aberrant
gene expression, inflammatory cell (neutrophil) influx,
and pathogenesis in multiple organs. These studies
strongly support that neutral lipid metabolism in
macrophages contributes to organ inflammation and
pathogenesis. (Am J Pathol 2006, 169:916–926; DOI:
10.2353/ajpath.2006.051327)
Macrophages produce and secrete cytokines, chemo-
kines, and growth factors that influence gene expression,
cell proliferation/differentiation, and apoptosis in organ
tissues through paracrine and autocrine mechanisms,
making them vitally important to the physiological func-
tions of multiple organs. Many diseases are tightly asso-
ciated with malformation and malfunction of macro-
phages within organs. Design and establishment of a
system to specifically express “genes of interest” in mac-
rophages in a temporal/spatial fashion will greatly assist
in understanding the molecular mechanisms of macro-
phage differentiation/maturation and the functional roles
of macrophages in disease formation. The tetracycline-
inducible transgenic mouse system has proven to be
very effective in inducing genes of interest in a temporal
and spatial manner. In this system, “activator” transgenic
mice bear the reverse tetracycline-responsive transacti-
vator (rtta) fusion protein under control of a cell type-
specific promoter. The rtta expression is restricted to
specific cell types in transgenic mice. In a separate trans-
genic mouse line, the gene of interest is under control of
the tet operator DNA-binding sequence that is linked to a
minimal promoter. After crossbreeding, expression of the
gene of interest can be precisely controlled by addition or
removal of tetracycline or doxycycline in double trans-
genic mice. This strategy has been proven to be very
effective in many organ systems, including the lung.1,2
To design a tetracycline-controlled macrophage-spe-
cific system, the key is to select a macrophage-specific
promoter. It has been reported previously that the c-fms
gene, which encodes the receptor for macrophage col-
ony-stimulating factor (CSF-1), is selectively expressed in
macrophage and trophoblast cell lineages. In a trans-
genic mouse study, 7.2-kb of the 5-flanking regulatory
sequence and the downstream intron 2 of the c-fms gene
have been defined to direct specific expression of the
green fluorescent protein (GFP) reporter gene in the
same locations as the endogenous gene, therefore pro-
viding an ideal DNA sequence to direct gene expression
in mononuclear phagocyte lineage during embryonic de-
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velopment and in bone marrow, peripheral blood, and all
adult tissues.3
Cholesteryl esters and triglycerides are important com-
ponents in neutral lipids, which can be hydrolyzed by
lysosomal acid lipase (LAL) in the lysosome of cells to
generate free cholesterol and free fatty acids. After LAL
cleaves these lipids, they exit the lysosome and enter the
cytosol. An lal/ mouse model has been generated by
gene targeting.4 lal/ mice developed pathogenic phe-
notypes in multiple organs, including lung, liver, spleen,
adrenal glands, and small intestine.4–6 These pathogenic
phenotypes are caused by abnormal gene expression.
For example, Affymetrix GeneChip microarray analysis of
lal/ mice showed aberrant gene expression for inflam-
matory cytokines/chemokines, endopeptidases (eg, ma-
trix metalloproteinases), apoptosis inhibitors, transcrip-
tion factors, and oncogenes in the lung.5,7 These gene
profile changes correlated well with pulmonary pheno-
type progression in the lal/ lung in an age-dependent
manner. It is known that many metabolic derivatives of
free cholesterols and free fatty acids serve as hormonal
ligands for nuclear receptors and transcription factors
that have profound and diverse functions in gene regu-
lation, cell proliferation, differentiation, and apoptosis. In
a rescue study, treatment of peroxisome proliferator-ac-
tivated receptor  (PPAR) ligands (downstream metab-
olites of LAL) significantly improved lal/ pulmonary
inflammation and aberrant gene expression, suggesting
that inflammation-triggered pathogenesis during LAL de-
ficiency is partially caused by inactivation of PPAR be-
cause of a lack of ligand production. Because abnormal
appearance of macrophages is the major manifestation
of lal/ mice within multiple organs, we hypothesize that
a deficiency of LAL greatly affects the normal functions
of macrophages and leads to various pathogenic
phenotypes.
To test this hypothesis, doxycycline-controlled c-fms
7.2-kb promoter/intron2-rtTA and (tetO)7-CMV-hLAL
transgenic mouse lines were generated. After cross-
breeding the double transgenic lines into lal/ mice,
expression of hLAL in macrophages significantly amelio-
rated tissue inflammation, pathogenic phenotypes, and
aberrant gene expression in several organs, supporting a
concept that cholesteryl ester and triglyceride metabo-
lism is essential for the normal biological function of
macrophages.
Materials and Methods
Animal Care
All scientific protocols involving the use of animals in this
study have been approved by the Institution Animal Care
and Usage Committee and followed guidelines estab-
lished by the Panel on Euthanasia of the American Vet-
erinary Medical Association. Protocols involving the use of
recombinant DNA or biohazardous materials followed
guidelines established by the National Institutes of Health.
Animals were housed in an Institution Animal Care and
Usage Committee-approved facility. Animals were regularly
screened for common respiratory pathogens and murine
viral hepatitis. Experiments involving animal sacrifice used
CO2 narcosis to minimize animal discomfort.
Generation of Transgenic Mice
To generate c-fms-rtTA transgenic mice, the cDNA frag-
ment of rtTA was amplified by polymerase chain reaction
(PCR) using a downstream primer (5-AAGGAAAAAAG-
CGGCCGCGTACATTGAGCAACTGAC-3) and an up-
stream primer (AAGGAGGGCCCGCCACCATGTCTAG-
ATTAGATAAA-3). The PCR product was digested with
ApaI/NotI and subcloned into the p7.2MCS construct
containing the 7.2-kb c-fms promoter/intron2 fragment.
The c-fms-rtTA expression cassette containing the 7.2-kb
c-fms promoter/intron2 fragment, the rtTA cDNA, and the
SV40 polyadenylation signaling sequence was microin-
jected into eggs of FVB/N mice by the Transgenic Core
Facility at the University of Cincinnati, College of Medi-
cine. Founder lines were identified by a pair of primers
covering the 7.2-kb c-fms promoter/intron2 sequence (5-
TGATTGAAGGGTCCAGACTCATTC-3) and an rtTA
cDNA coding region sequence (5-AGTGTAGGCT-
GCTCTACACCAAGC-3).
To generate the (tetO)7-CMV-hLAL transgenic mouse
line, hLAL cDNA was amplified by PCR using a down-
stream primer (5-AAGGAAAAAGCGGCCGCTTATCAC-
TTGTCATCGTCGTCCTTGTAGTCCTGATATTTCCTCAT-
TAG-3) that contains a Flag sequence and an upstream
primer (5-CTAGACGCGTGCCACCATGAAAATGCGGT-
TCTTGG-3). The PCR product was digested with MluI/
NotI and subcloned downstream of the CMV minimal
promoter linked to seven Tet-responsive elements (7
TRE) at the MluI and NotI sites in the pTRE2 vector (BD
Bioscience-Clontec, Mountain View, CA). The expression
cassette containing the CMV promoter, the hLAL cDNA,
and the -globin polyadenylation signaling sequence
was excised and purified for microinjection into FVB/N
mice. Founder lines were identified by a pair of primers
covering the pTRE2 vector sequence (5-ACGCCATC-
CACGCTGTTTTG-3) and the hLAL cDNA sequence (5-
AGACAACTGGTTTGGGACCTTTG-3).
Isolation of Macrophages from Bronchoalveolar
Lavage Fluid (BALF) for Antibody Array Analysis
BALF was collected by perfusing each lung of wild-type
or lal/ mice with 1-ml aliquots of 0.9% sodium chloride
and withdrawing back the fluids three times. BALFs from
eight mice were combined and centrifuged for 5 minutes
at 1000 rpm and 4°C to collect macrophage pellets.
Purified macrophages were lysed for protein preparation.
After determination of protein concentrations, expression
levels of cytokines/chemokines were determined with the
Mouse Inflammation Antibody Array System from RayBio
Cytokine Antibody Array service (RayBiotech, Inc.,
Norcross, GA). Fold changes of cytokines and chemo-
kines between lal/ and wild-type macrophages were
analyzed by the software service from the same com-
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pany. The intensity of each signal was scanned and
normalized with backgrounds.
Isolation of Total RNA from Whole Lung Tissue
for Reverse Transcriptase (RT)-PCR Assay
Whole lung tissues were dissected from doxycycline-
treated (4-month) or untreated c-fms-rtTA/(tetO)7-CMV-
hLAL double mice or c-fms-rtTA/(tetO)7-CMV-hLAL/lal/
triple mice after mice were anesthetized by intraperito-
neal injection. Whole lung tissues were homogenized in
RLT lysis buffer for total RNA purification as recom-
mended by the manufacturer (Qiagen, Valencia, CA).
Total RNAs were purified using the Qiagen total RNA
purification kit as recommended by the manufacturer
(Qiagen).
For semiquantitative RT-PCR assay, total RNAs were
used to detect mRNA expression by a SuperScript One-
Step RT-PCR Kit (Invitrogen, Carlsbad, CA). Primers for
RT-PCR amplification of Api6, MafB, MMP-9, MMP-12,
Spi-C, and GAPDH genes were described previously.7
Primers for tumor necrosis factor- (TNF-), interleukin
(IL)-1, IL-6, CCL7, and CXCL1 were purchased from
SuperArray Bioscience (Frederick, MD). Primers for RT-
PCR amplification of hLAL were an upstream primer cor-
responding to the hLAL cDNA sequence (5-CACATTC-
TCCTGCTGGAACTTCTG-3) and a downstream primer
corresponding to the pTRE vector sequence (5-CCTG-
AAAACTTTGCCCCCTC-3).
Tissue Lipid Extraction and Determination of
Cholesteryl Ester and Triglyceride
Concentrations
Total tissue lipids were extracted from the liver and small
intestine by the Folch method.4 Concentrations of cho-
lesteryl esters and triglycerides were determined as pre-
viously described.6,8
Liver Extraction and Lysosomal Acid Lipase
Activity Assays
Liver tissues were homogenized, sonicated, and ex-
tracted in tissue lysis buffer (100 mmol/L NaPO4, pH 6.8,
1 mmol/L ethylenediamine tetraacetic acid, 10 mmol/L
dithiothreitol, 0.5% NP-40, and 0.02% sodium azide) fol-
lowed by centrifugation at 4°C, 10,000  g for 15 min-
utes. Aliquots of the supernatant were stored at 20°C
until assayed. Protein concentration of the liver extract
was determined by the BCA assay following the protocol
from manufacturer (Pierce, Rockford, IL). hLAL activities
were estimated with the fluorogenic substrate 4-methyl-
umbelliferyl-oleate (4-MUO). The assay was performed in
a microtiter plate at 37°C at pH 5.5 using a 4-methylum-
belliferone (4-MU) standard curve. In brief, 4-MUO in
hexane (100 mg/ml) was diluted 1 to 100 in 4% Triton
X-100. The assay used 50 l of the diluted substrate, 25
l of diluted liver extract, and 125 l of assay buffer (0.2
mol/L Na2Ac and 0.01% Tween 80, pH 5.5) at 37°C for 30
minutes. The reaction was stopped by adding 100 l of
0.75 mol/L Tris, pH 8.0. The resulting fluorescence signal
was detected at excitation 360 nm and emission 460 nm.
The relative fluorescence units from each sample were
directly compared with that of the standard curve. One
unit of activity is defined as producing 1 mol/L 4-MU per
minute. All assays were conducted in duplicate, and the
results were the mean of three experiments. Assays were
linear within the time frame used, and less than 10% of
substrates were cleaved.
Oil Red-O Staining
Frozen tissue sections were prepared from liver and in-
testine after a standard cryostat procedure. Tissue sec-
tion slides were stained with Oil Red-O solution (0.5% in
propylene glycol) in a 60°C oven for 10 minutes and
placed in 85% propylene glycol for 1 minute; slides were
counterstained in hematoxylin.
Immunohistochemistry
Tissues from liver, intestine, and lung were collected after
mice were anesthetized. For lung tissue preparation,
lungs were inflation-fixed with 4% paraformaldehyde in
phosphate-buffered saline overnight at 4°C. All tissues
were washed with phosphate-buffered saline and dehy-
drated by a series of increasing ethanol concentrations,
followed by paraffin embedding. Sections were incu-
bated with rat anti-mouse Ly6G antibody (1:500; BD Bio-
sciences PharMingen) or rabbit anti-mouse macrophage
antibody (1:200; Accurate Chemical & Scientific Co.,
Westbury, NY) as the primary antibody. Tissue sections
were washed and treated with biotinylated secondary
antibodies. To visualize signals, interactions were de-
tected with the Vectastain Elite ABC kit (Vector Labora-
tories, Burlingame, CA) according to the manufacturer’s
instructions.
Results
Inflammatory Cytokine/Chemokine Expression in
Macrophages of Wild-Type and lal/ Mice
Abnormal appearance and accumulation of macro-
phages in multiple organs suggests that they play a
major role in contributing to pathogenesis in lal/
mice. These pathogenic phenotypes are associated
with inflammation. To establish that macrophages are a
primary source for mediating inflammation in lal/
mice, wild-type and lal/ macrophages were isolated
from BALF. Macrophages were lysed by using cell lysis
buffer (from RayBiotech). The expression levels of var-
ious cytokines and chemokines in macrophages were
measured by inflammatory antibody array analysis (Ta-
ble 1). Expression levels of many cytokines and che-
mokines were changed (most were up-regulated) in
lal/ macrophages in comparison with wild-type mac-
rophages. This strongly suggests that the LAL activity
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in macrophages controls production of pro-inflamma-
tory cytokines and chemokines, and malfunction of
macrophages has a primary effect in lal/ pathogen-
esis in various organs.
Generation of c-fms-rtTA Transgenic Mice
To test the primary role of macrophages in lal/ patho-
genesis, we designed a system to specifically express
hLAL in macrophages. This is achieved by subcloning
the cDNA fragment of rtTA into the p7.2MCS construct
that contains the 7.2-kb c-fms promoter/intron2 fragment
(Figure 1A). The c-fms-rtTA expression cassette DNA
containing the 7.2-kb c-fms promoter/intron2 fragment,
the rtTA cDNA, and the SV40 polyadenylation signaling
sequence was isolated and microinjected into eggs of
FVB/N mice. Seven positive clones were identified after
screening by PCR using a pair of primers covering the
7.2-kb c-fms promoter/intron2 sequence and the rtTA
cDNA sequence (Figure 1B). The clones are designated
as c-fms-rtTA transgenic founder lines. Among these
founders, only two founders showed positive transgene
F1 generations. Founder 77 was chosen for further char-
acterization of rtTA expression in the macrophage lin-
eage compartment. Alveolar macrophages, peritoneal
macrophages, and bone marrow cells were isolated from
this founder line for mRNA purification. A pair of primers
corresponding to the rtTA cDNA sequence was used for
detection of rtTA expression by RT-PCR. Both macro-
phages and bone marrow cells showed rtTA expression
(Figure 1C). As a control, no expression was detected in
isolated AT II cells (data not shown).
Generation of (tetO)7-CMV-hLAL Transgenic
Mice
In parallel, the cDNA fragment of hLAL was subcloned into
the pTRE construct that contains seven copies of the tet
Table 1. Aberrant Expression of Cytokines/Chemokines in
lal/ Bronchoalveolar Macrophages in Antibody
Array Analysis
Name
WT BALF
macrophage
KO BALF
macrophage
POS 27,135.08 27,135.08
NEG 0.00 0.00
BLC 0.00 1055.47
CD30L 70.50 868.94
Eotaxin 2288.00 1493.28
Eotaxin-2 3233.32 1010.42
FAS ligand 3998.55 1174.42
Fractalkine 4590.73 3100.23
G-CSF 5598.22 5100.65
GM-CSF 1557.38 5563.10
IFN- 1734.26 1627.01
IL-1 2075.22 2556.13
IL-1 0.00 364.96
IL-2 0.00 93.26
IL-3 0.00 0.00
IL-4 0.00 685.93
IL-6 0.00 0.00
IL-9 0.00 0.00
IL-10 0.00 0.00
IL-12-p40/p70 1111.31 322.02
IL-12-p70 3417.25 4985.92
IL-13 0.00 6295.13
IL-17 0.00 2587.81
I-TAC 0.00 1488.35
KC 0.00 343.14
Leptin 0.00 371.30
LIX 0.00 1621.38
Lymphotactin 0.00 0.00
MCP-1 0.00 0.00
M-CSF 0.00 56.66
MIG 0.00 0.00
MIP-1- 0.00 963.26
MIP-1- 3893.44 10,003.87
RANTES 2591.14 7414.30
SDF-1 2509.11 4039.91
TCA-3 1496.49 4414.37
TECK 0.00 1594.64
TIMP-1 0.00 1476.38
TIMP-2 0.00 0.00
TNF- 0.00 0.00
sTNF RI 0.00 0.00
sTNF RII 0.00 0.00
POS, positive control; NEG, negative control; BLC, B-lymphocyte
chemoattractant; G-CSF, granulocyte colony stimulating factor; GM-
CSF, granulocyte-macrophage colony stimulating factor; IFN, interferon;
I-TAC, interferon-inducible T-cell -chemoattractant; KC, keratinocyte
cytokine; LIX, LPS-induced CXC chemokine; M-CSF, macrophage
colony stimulating factor; MIG, monokine induced by -interferon; MIP,
macrophage inflammatory protein; RANTES, regulated upon activation,
normal T-cell expressed, and presumably secreted; SDF, stromal
cell-derived factor; TCA, T-cell activation; TECK, thymus-expressed
chemokine; TIMP, tissue inhibitor of metalloproteinases.
Figure 1. Generation of c-fms rtTA transgenic mice. A: Illustration of c-fms-
rtTA transgene design. B: PCR genotyping of c-fms-rtTA transgenic founders.
MW, molecular weight marker; NC, negative control from tail DNAs of a
negative pup; PC, positive control using the c-fms-rtTA construct as a DNA
template. C: Expression of rtTA mRNA in peritoneal macrophages, lung
macrophages, and bone marrow cells of c-fms-rtTA transgenic mice.
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operator DNA binding sequence linked to a minimal CMV
promoter and -globin polyA signals (Figure 2A). The ex-
pression cassette of the (tetO)7-CMV-hLAL construct was
microinjected into eggs of FVB/N mice. Six positive clones
were obtained by PCR using a pair of primers covering the
hLAL cDNA and pTRE sequences (Figure 2B). These
clones were designated as (tetO)7-CMV-hLAL founder
lines. All founders showed positive F1 generations. Founder
556 was crossbred with the c-fms Founder 77 line to
obtain double transgenic mice (Figure 2C). After treat-
ment of c-fms-rtTA/(tetO)7-CMV-hLAL double trans-
genic mice with doxycycline-treated food for 1 month,
macrophages (from peritoneal and lung lavage fluid)
and bone marrow cells showed induced hLAL mRNA
expression (Figure 2D). Increased hLAL mRNA expres-
sion level was also observed in liver, lung, and intes-
tinal tissues that contain macrophages (Figure 2E).
Macrophage-Specific Expression of hLAL
Reduced Neutral Lipid Accumulation in c-fms-
rtTA/(tetO)7-CMV-hLAL;lal/ Triple Mice
LAL deficiency in mice caused massive neutral lipid ac-
cumulation in Kupffer cells in the liver, lamina propria
(inside of epithelia villia), and the base of villia in the
Figure 3. Macrophage-specific expression of hLAL reduced neutral lipid
accumulation in the liver of c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice.
Frozen sections of liver were stained with Oil Red-O. Massive neutral lipid
accumulation (red color) was detected in Kupffer cells (macrophages) in
livers of lal/ (B) and c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple mice (C)
without doxycycline treatment as indicated by asterisks. D: Doxycycline
treatment significantly reduced Oil Red-O staining in c-fms-rtTA/(tetO)7-
CMV-hLAL;lal/ triple mice. Wild-type lal/ mice (A) were the negative
control for Oil Red-O staining.
Figure 4. Macrophage-specific expression of hLAL reduced neutral lipid
accumulation in the intestine of c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple
mice. Frozen sections of small intestine were stained with Oil Red-O. Massive
neutral lipid accumulation (red color) was detected in the lamina propria and
the base of villi in the intestine of lal/ (B) and c-fms-rtTA/(tetO)7-CMV-
hLAL;lal/ triple mice (C) without doxycycline treatment as indicated by
asterisks. D: Doxycycline treatment significantly reduced Oil Red-O staining
in the c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple mice. Wild-type lal/
mice (A) were the negative control for Oil Red-O staining.
Figure 2. Generation of (tetO)7-CMV-LAL transgenic mice. A: Illustration of
(tetO)7-CMV-hLAL transgene design. B: PCR genotyping of (tetO)7-CMV-
hLAL transgenic founders. MW, molecular weight marker; NC, negative
control from tail DNAs of a negative pup; PC, positive control using (tetO)7-
CMV-hLAL construct as a DNA template. C: PCR genotyping of c-fms-rtTA/
(tetO)7-CMV-hLAL double transgenic mice. MW, molecular weight marker.
D: Expression of hLAL mRNA in bronchio-alveolar macrophages (BAL Mac),
peritoneal macrophages (P Mac), and bone marrow (BM) cells. E: Expres-
sion of hLAL mRNA in lung, intestine, and liver of c-fms-rtTA/(tetO)7-CMV-
hLAL double transgenic mice after doxycycline (Dox) treatment (). Un-
treated () double transgenic mice were the control.
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intestine and in macrophages and alveolar type II cells in
the lung.4–6,8 To test whether deficiency of LAL in mac-
rophages is responsible for lipid accumulation, c-fms-
rtTA/(tetO)7-CMV-hLAL double transgenic mice were in-
troduced into the lal/ background by crossbreeding to
generate c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple mice.
Without doxycycline treatment, neutral lipid accumulation
was still observed in the liver and the intestine of c-fms-
rtTA/(tetO)7-CMV-hLAL;lal/ triple mice, similar to lal/
mice (Figures 3 and 4; identified in the asterisk area).
However, expression of hLAL in macrophages induced
by doxycycline treatment significantly reduced neutral
lipid accumulation in the same liver and intestinal areas of
triple lal/ mice by Oil-Red-O staining (Figures 3 and 4).
This clearly indicates the effectiveness of doxycycline-
induced hLAL activity in degrading neutral lipids in triple
lal/ mice.
Macrophage-Specific Expression of hLAL
Restored the LAL Activity in c-fms-rtTA/(tetO)7-
CMV-hLAL;lal/ Triple Mice
To monitor changes of neutral lipid degradation at the
biochemical level in addition to Oil-Red-O staining,
concentrations of cholesteryl esters and triglycerides
were measured in doxycycline-treated and untreated
triple mice. In agreement with Figures 3 and 4, con-
centrations of cholesteryl esters and triglycerides were
significantly higher in single lal/ and triple lal/
mice without doxycycline treatment. Expression of
hLAL in macrophages by doxycycline treatment signif-
icantly decreased concentrations of cholesteryl esters
and triglycerides (Figure 5A). A direct measurement of
the LAL enzymatic activity using the fluorogenic sub-
strate 4-MUO was also performed. Proteins were
isolated from the livers of doxycycline-treated and
untreated c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple
mice. Wild-type and lal/ mice were used as controls.
Although doxycycline-untreated triple mice showed a
similar LAL activity with that in lal/ mice, treatment of
doxycycline partially restored the LAL activity (Figure
5B). Taken together, the neutral lipid metabolism was
partially recovered by expression of hLAL in macro-
phages of c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple
mice.
Macrophage-Specific Expression of hLAL
Reduced Neutrophil Infiltration in c-fms-rtTA/
(tetO)7-CMV-hLAL;lal/ Triple Mice
Neutrophil infiltration is a major inflammatory manifesta-
tion in lal/ mice.5,7 Triple lal/ mice were treated with
doxycycline for 3 months to induce hLAL expression in
macrophages. The liver, intestine, and lung were exam-
ined for assessment of neutrophil infiltration because
these organs displayed dramatically pathogenic pheno-
types during LAL deficiency.4–6,8 As demonstrated in
Figure 6, all three organs from triple lal/ mice without
doxycycline treatment exhibited significant neutrophil in-
filtration versus wild-type mice. After doxycycline induc-
tion in triple lal/ mice, expression of LAL in macro-
phages significantly attenuated neutrophil influx into liver,
intestine, and lung tissues. These results indicate that
LAL activity in macrophages plays an essential role in
controlling tissue inflammation in various organs during
LAL deficiency.
Macrophage-Specific Expression of hLAL
Reduced Liver Pathogenesis in
c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ Triple Mice
We reported previously that LAL deficiency in mice
caused severely pathogenic phenotypes and enlarge-
Figure 5. Macrophage-specific expression of hLAL restored the LAL activity in c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple mice. A: Concentrations of cholesteryl
esters (left) and triglycerides (right) in the liver and small intestine of wild-type mice, lal/ mice, untreated (Dox off) triple lal/ mice, and doxycycline-treated
(Dox on) triple lal/ mice. B: The liver LAL activity in wild-type mice, lal/ mice, untreated (Dox off) triple lal/ mice, and doxycycline-treated (Dox on)
triple lal/ mice were measured using the fluorogenic substrate, 4-MUO in vitro.
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ment in the size of the liver in association with foamy
macrophage formation (Kupffer cells).4,6,8 To specifically
address the functional role of macrophages in liver
pathogenic processes, c-fms-rtTA/(tetO)7-CMV-hLAL;
lal/ triple mice with or without doxycycline treatment
were examined. At the histological level, triple lal/mice
without doxycycline treatment displayed massive foamy
Kupffer cell formation (Figure 7C), similar to lal/ mice
(Figure 7B). After 3 months of doxycycline treatment be-
ginning from 1 month of age, the size of foamy Kupffer
cells was significantly reduced (Figure 7D). It appears
that lipid-filled hepatocytes remained unchanged in
treated triple lal/ mice, indicating cell type-specific
hLAL rescue in the liver. This is confirmed by immuno-
histochemical staining using macrophage-specific anti-
body, in which positively stained and lipid-stored macro-
phages were significantly reduced in the livers of treated
triple lal/ mice (Figure 7, E–H). These results suggest
that LAL activity in macrophages contribute to lal/
pathogenesis in the liver.
Macrophage-Specific Expression of hLAL
Reduced Intestine Pathogenesis in c-fms-rtTA/
(tetO)7-CMV-hLAL;lal/ Triple Mice
To address the functional role of macrophages in the
intestinal pathogenic process, a histological study of in-
testines from c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple
mice was performed. Similar to lal/ mice (Figure 8B),
macrophage accumulation was observed in the lamina
propria (inside of epithelia villia) and the base of villia in
doxycycline-untreated triple lal/ mice (Figure 8C, iden-
tified in the asterisk area). Doxycycline treatment signifi-
cantly reduced both the size and the number of macro-
phages in triple lal/ mice (Figure 8D).
Macrophage-Specific Expression of hLAL
Reduced Lung Pathogenesis in
c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ Triple Mice
In the lung, alveolar space enlargement (emphysema) was
closely associated with macrophage proliferation in lal/
mice.5 Extracellular membrane degrading enzymes such
as MMP-9 and MMP-12 were highly expressed in the lal/
lung during pulmonary pathogenesis. To assess the func-
tional role of macrophages in this pulmonary pathogenic
process, histological analyses of c-fms-rtTA/(tetO)7-CMV-
hLAL;lal/ triplemice with or without doxycycline treatment
were performed. In untreated triple mice (Figure 9C), the
alveolar space area was significantly larger than that seen
in the wild-type lung (Figure 9A), similar to that seen in the
single lal/ lung (Figure 9B). Expression of hLAL in mac-
rophages for 5months significantly reversed emphysema in
doxycycline-treated triple lal/ mice (Figure 9D). A quan-
titative analysis revealed a reduced ratio between the alve-
olar airspace area and the parenchyma area in the lal/
lung after macrophage hLAL expression (Figure 9E). In the
immunohistochemical staining study using a macrophage-
specific antibody, positively stained macrophages were
significantly reduced in the lung of doxycycline-treated ver-
sus untreated triple lal/ mice (Figure 9F). Therefore, LAL
activity in macrophages is essential for maintaining normal
alveolar structure and function in the lung.
Macrophage-Specific Expression of hLAL
Reduced Aberrant Gene Expression in c-fms-
rtTA/(tetO)7-CMV-hLAL;lal/ Triple Mice
Pathogenic phenotypes are caused by aberrant gene
expression in lal/ mice. Gene profile changes have
Figure 6. Macrophage-specific expression of
hLAL reduced neutrophil infiltration in c-fms-
rtTA/(tetO)7-CMV-LAL;lal/ triple mice. Paraf-
fin embedded liver, intestine, and lung tissue
sections from wild-type (lal/) and untreated
(Dox) or doxycycline-treated (Dox) c-fms-
rtTA/(tetO)7-CMV-LAL;lal/ triple mice were
immunostained with Ly6G antibody. Small black
dots in various sections represent stained
neutrophils.
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previously been assessed in the lal/ lung by Affymetrix
GeneChip microarray analysis. This analysis identified
aberrant expression of many genes during LAL defi-
ciency. These gene products include cytokines/chemo-
kines, MMPs, apoptosis inhibitors, transcription factors,
and oncogenes.5,7 Using these molecules as biomarkers
to assess how expression of hLAL in macrophages cor-
rects aberrant gene expression in the lung, liver, and
intestine, mRNA expression levels were examined by
RT-PCR. As demonstrated in Figure 10A, Api6, MMP-9,
MMP-12, MafB, and Spi-C were highly overexpressed in
the lung, liver, and intestine of c-fms-rtTA/(tetO)7-CMV-
hLAL;lal/ triple mice, in a manner similar to single lal/
mice.7 Expression of hLAL by doxycycline treatment in
macrophages significantly reduced the expression levels
of these molecules in triple lal/mice. This indicates that
these molecules contribute to pathogenic progression in
multiple organs during LAL deficiency. A group of cyto-
kines and chemokines were also up-regulated in lungs of
lal/ mice as we previously reported.5 A set of cyto-
kines/chemokines in this group (TNF-, CCL7, and
CXCL1) showed significant reduction in triple lal/ mice
after doxycycline treatment in the lung, liver, and intes-
tine. Another set of cytokines/chemokines in this group
(IL-1 and IL-6) only showed changes in the lung but not
in the intestine and liver, after doxycycline treatment (Fig-
ure 10B). This observation suggests that pathogenesis in
different organs share common genes and pathways with
certain distinctions during LAL deficiency.
Discussion
It is intriguing that many seemingly unrelated disease
phenotypes of various organs coexist in lal/ mice.
Some common cellular and molecular mechanisms must
exist to link these pathogenic processes together. Based
on previous observations, abnormal macrophages were
observed in multiple organs in lal/ mice, including the
liver, intestine, and lung.4–8 Therefore, macrophages
play a central role in pathogenic progression during LAL
deficiency. Aberrant expression levels of multiple inflam-
matory cytokines and chemokines were monitored in
association with lal/ macrophages (Table 1). These
inflammatory molecules can change the local microenvi-
ronment by binding to the residential cells to affect gene
expression (Figure 10) and cause pathogenic pheno-
types in various organs. Establishment of an in vivo mac-
rophage-specific controllable system is essential to elu-
cidate and dissect molecular, cellular, and physiological
mechanisms in lal/mice. In this report, we generated a
c-fms 7.2-kb promoter/intron2-rtTA transgenic line, in
which rtTA expression is restricted to macrophages as
previously reported.3 In the c-fms 7.2-kb promoter/in-
tron2-directed GFP transgenic system, GFP has been
detected in Kupffer cells of the liver, lamina propria of the
small intestine, and bronchio-alveolar macrophages of
the lung. This expression pattern overlaps with abnormal
macrophage malformation in lal/ mice as determined
by Oil Red-O staining of neutral lipids.4–6,8 Macrophages
Figure 7. Macrophage-specific expression of hLAL reduced liver pathogen-
esis in c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice. Histological (A–D)
and immunohistochemical (E–H) comparison of liver sections from un-
treated (C and G) and doxycycline-treated (D and H) c-fms-rtTA/(tetO)7-
CMV-LAL;lal/ triple mice. Wild-type (A and E) and lal/ (B and F) mice
were used as negative and positive controls, respectively, for foamy Kupffer
cell formation. Kupffer cells are indicated by arrows.
Figure 8. Macrophage-specific expression of hLAL reduced intestine patho-
genesis in c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice. Histological com-
parison of intestine sections from untreated (C) and doxycycline-treated (D)
c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice. Wild-type (A) and lal/ (B)
mice were negative and positive controls.
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in these areas appear foamy and lipid filled. Therefore,
the c-fms 7.2-kb promoter/intron2 DNA sequence is ideal
for directing LAL expression in vivo to correct macroph-
age-mediated pathogenic phenotypes in lal/ mice. Af-
ter crossbreeding these mice with the (tetO)7-CMV-hLAL
transgenic mouse line, the induced expression level of
hLAL was readily detectable by RT-PCR in macrophages
and in bone marrow cells (Figure 2D), as well as in liver,
intestine, and lung tissues that contain macrophages
(Figure 2E). The LAL enzymatic activity was restored with
correction of neutral lipid metabolism (Figure 5).
After crossbreeding c-fms-rtTA/(tetO)7-CMV-hLAL
double transgenic mice with lal/ mice, expression of
hLAL in lal/ macrophages by doxycyline treatment sig-
nificantly reduced neutral lipid accumulation in the liver
and intestine as assessed by Oil Red-O staining (Figures
3 and 4) in association with attenuated inflammatory neu-
trophil infiltration. Neutrophil infiltration has been ob-
served in the liver, intestine, and lung of lal/ mice
(Figure 6), suggesting that inflammation is a major trigger
for pathogenic progression in various lal/ organs. In
general, inflammation starts with stimulation of vascular
endothelial cells by pro-inflammatory cytokines and che-
mokines generated by either regional macrophages or
residential cells.9 Cytokines and chemokines regulate
leukocyte trafficking, homing, and migration. The process
begins with activating intracellular signaling cascades in
endothelial cells, which influences expression of an array
of inflammation-associated genes, including a variety of
adhesion molecules. Increased expression of adhesion
molecules facilitates migration and adhesion of phago-
cytic neutrophils to vascular endothelium at vessel sites
adjacent to inflammatory sites. Neutrophils migrate
through vessel walls to infiltrate inflammatory tissues.
Activated neutrophils produce both free radicals (eg,
superoxide) and proteinases (eg, neutrophil elastase and
MMPs) causing tissue damage. Correction of neutrophil
infiltration and pathogeneses in multiple organs by restor-
Figure 9. Macrophage-specific expression of hLAL reduced pulmonary
pathogenesis in c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice. A–D: Histo-
logical comparison of lung sections from untreated (C) and doxycycline-
treated (D) c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice. Wild-type (A)
and lal/ (B) mice were controls. E: Morphometric analysis of alveolar
space in wild-type (lal/) mice, lal/ mice, and untreated (Dox) and
doxycycline-treated (Dox) c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice.
Differences between ratios of airspace/parenchyma were analyzed by anal-
ysis of variance. P  0.05. Values are means  SD; n 	 3 (mice). F:
Immunohistochemical staining comparison of lung sections from untreated
and doxycycline-treated c-fms-rtTA/(tetO)7-CMV-LAL;lal/ triple mice us-
ing an antibody specifically against macrophage surface antigens. Positively
stained cells from various microscopic fields of each sample were counted.
Differences between untreated (Dox) and doxycycline-treated (Dox)
samples were analyzed by analysis of variance. P 0.05. Values are means
SD; n 	 3 (mice).
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ing LAL production in c-fms-rtTA/(tetO)7-CMV-hLAL;
lal/ triple mice suggests that macrophages play an
important role in controlling inflammation-triggered
pathogenesis through production and secretion of cyto-
kines and chemokines. This has been confirmed by RT-
PCR analysis in the lung, liver, and intestine (Figure 10B).
Although migrating macrophages are a major source and
site for production of cytokines and chemokines, partial
correction of pathogenic phenotypes in c-fms-rtTA/
(tetO)7-CMV-hLAL;lal/ triple mice suggests that other
residential cell types in these organs also contribute to
aberrant production of inflammatory cytokines and che-
mokines leading to tissue pathogenesis. This has been
confirmed by the observation that TNF- and IL-6 were
up-regulated in the lung but not in macrophages (Table
1). Interactions between macrophages and residential
cells are important for tissue pathogenic development in
lal/ mice.
Based on previous and current observations, it ap-
pears that neutral lipid metabolism is essential for con-
trolling malformation and malfunction of macrophages
caused by aberrant gene expression in lal/ mice. De-
ficiency of LAL in macrophages blocks the normal syn-
thesis of various hormonal ligands for nuclear receptors
such as PPAR and other transcription factors such as
nuclear factor E2 p45-related factor 2 (Nrf2).10–13 Treat-
ment with PPAR ligands significantly attenuated lal/
pulmonary inflammation and aberrant gene expression in
the lungs.7 In addition to PPAR, there is emerging evi-
dence indicating that other lipid mediators such as Nrf2
contribute to cyclooxygenase product function in inflam-
mation.13 Expression of hLAL in macrophages of c-fms-
rtTA/(tetO)7-CMV-hLAL;lal/ triple mice restored the
production of ligands for nuclear receptors and lipid-
mediating transcription factors that suppress synthesis
and secretion of pro-inflammatory cytokines and chemo-
kines. As a consequence, pathogenic phenotypes were
ameliorated in various lal/ organs. Recently, biochem-
ical pathways were identified that use polyunsaturated
fatty acids to generate resolvins and protectins that can
expedite inflammatory resolution.14 These mediators
might be regulated and enhanced by hLAL. Expression
of hLAL in macrophages may restore these pathways.
In addition to the cytokines, chemokines, and lipid-
mediated nuclear receptors/transcription factors men-
tioned above, other common molecules also contribute to
lal/ pathogenic processes in various organs. While
studying the relationship between aberrant gene expres-
sion and pathogenic progression in the lal/ lung, a set
of genes was identified with aberrant expression, includ-
ing Api6, MMP-9, MMP-12, MafB, and Spi-C.7 To see
whether aberrant expression of these genes occurs in
other organs, RT-PCR analysis was performed. Interest-
ingly, Api6, MMP-9, MMP-12, MafB, and Spi-C were all
up-regulated in the liver and intestine in addition to the
lung. In c-fms-rtTA/(tetO)7-CMV-hLAL;lal/ triple mice,
doxycycline treatment significantly reduced expression
of these molecules in all tested organs (Figure 10A). Api6
has been shown to be an apoptotic inhibitor with a mo-
lecular weight of 37 kd (331 amino acids) and belongs to
the scavenger receptor cysteine-rich superfamily.15,16
Transcription factor MafB belongs to the maf proto-onco-
gene family and is expressed in a wide variety of tissues
and encodes a 311-amino acid protein containing a typ-
ical bZip motif in its carboxy-terminal region.17,18 Spi-C
belongs to the Ets family of transcription factors.19 Ets
proteins comprise a large family of transcription factors
involved in a variety of cellular processes. The MMPs are
a group of zinc-dependent endopeptidases including
collagenases, gelatinases, and stromelysins.20 These
molecules cause a profound impact on tissue structure
by degrading components of the extracellular matrix.21,22
Although it is unclear how the LAL activity in macro-
phages affects pathogenic expression of these mole-
cules at this time, it is obvious that these molecules are
crucial to the pathogenic progress in various lal/ or-
gans. Study of these molecules will provide significant
insight into the molecular mechanisms and linkages be-
tween various pathogenic phenotypes in lal/ mice.
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